What is the Genentech Crenezumab Study for Alzheimer's Disease?
This is a Phase II multicenter study evaluating the long-term safety and tolerability of the drug crenezumab in patients with mild-to-moderate Alzheimer's disease.
What is the purpose of the Genentech Crenezumab Study?
To test long-term safety extension of Phase II Studies ABE4869g and ABE4955g in patients with mild to moderate Alzheimer's Disease.
Patients who participated in and completed the ABE486g or ABE 4955g Phase I clinical trial are eligible to participate.
If you are interested in learning more about the Crenezumab study, please call (401) 455-6403 or send an e-mail to: firstname.lastname@example.org.
For information on other current research studies at Butler Hospital please click here.